Orchid offers consumers the opportunity to screen embryos for a myriad of medical conditions to choose the “healthiest” egg for conception. Their proprietary testing model looks at 99% of an egg’s DNA in comparison to competitors’ >1% sequence scans. Investors include the CEOs of 23andme, Oscar,

I have been overhauling the previous website to a clean, elevated site that’s responsive and consistent across all platforms and social media. I’ve also solidified the company’s branding through printed collateral, trade show presence, and an organized asset library. This is an ongoing project.